Cargando…

Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids

We retrospectively identified 89 consecutive patients from January 2004 to January 2012 to investigate efficacy of direct intrahepatic portocaval shunt (DIPS) combined with inferior vena cava (IVC) stenting for sinusoidal obstruction syndrome (SOS) associated with hepatotoxicity of pyrrolizidine alk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Shihua, Chu, Jianguo, Huang, He, Yao, Kechun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020549/ https://www.ncbi.nlm.nih.gov/pubmed/30009181 http://dx.doi.org/10.1155/2018/9804582

Ejemplares similares

Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome
por: Zhou, Chun-Ze, et al.
Publicado: (2020)

Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wu, Fan, et al.
Publicado: (2021)

Direct intrahepatic portocaval shunt for refractory hepatic hydrothorax: a case report
por: Kawahara, Yo, et al.
Publicado: (2016)

Hepatotoxicity of Pyrrolizidine Alkaloid Compound Intermedine: Comparison with Other Pyrrolizidine Alkaloids and Its Toxicological Mechanism
por: Wang, Ziqi, et al.
Publicado: (2021)

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
por: Zhang, Wei, et al.
Publicado: (2021)

First Report of Fulminant Budd-Chiari Syndrome Treated by Direct Intrahepatic Portocaval Shunt in Vietnam
por: Nguyen, Thai Van, et al.
Publicado: (2021)

Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome
por: Wang, Chao, et al.
Publicado: (2019)

Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid
por: Tu, Hongfei, et al.
Publicado: (2022)

Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids
por: Du, Xiaofei, et al.
Publicado: (2023)

Identification of Toxic Pyrrolizidine Alkaloids and Their Common Hepatotoxicity Mechanism
por: Yan, Xinmiao, et al.
Publicado: (2016)

Hepatotoxicity of pyrrolizidine alkaloids in rats in relation to human exposure
por: Bolt, Hermann M.
Publicado: (2020)

Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome
por: Kan, Xuefeng, et al.
Publicado: (2016)

Active Transport of Hepatotoxic Pyrrolizidine Alkaloids in HepaRG Cells
por: Enge, Anne-Margarethe, et al.
Publicado: (2021)

Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes
por: Yang, Xiao-Qian, et al.
Publicado: (2019)

Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China
por: Shang, Haitao, et al.
Publicado: (2021)

Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome
por: Gao, Hong, et al.
Publicado: (2015)

Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update
por: Teschke, Rolf, et al.
Publicado: (2021)

Pyrrole-protein adducts – A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity
por: Ma, Jiang, et al.
Publicado: (2018)

The key role of gut–liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity
por: He, Yisheng, et al.
Publicado: (2021)

Congenital intrahepatic portocaval shunts and hypoglycemia due to secondary hyperinsulinism: a case report and review of the literature
por: Weigert, Alexander, et al.
Publicado: (2018)

Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports
por: Jiang, Minjie, et al.
Publicado: (2020)

Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study
por: Liu, Fang, et al.
Publicado: (2020)

Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wang, Xuan, et al.
Publicado: (2022)

Small-Diameter PTFE Portosystemic Shunts: Portocaval vs Mesocaval
por: Shields, Robert
Publicado: (1998)

Pyrrolizidine alkaloid-derived DNA adducts are common toxicological biomarkers of pyrrolizidine alkaloid N-oxides
por: He, Xiaobo, et al.
Publicado: (2017)

Budd-Chiari Syndrome Transplant, Meso-Atrial Shunt or Combined Portocaval Shunt With Cavo-Atrial Shunt
por: Hobbs, K. E. F.
Publicado: (1993)

Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum
por: Zhang, Lijie, et al.
Publicado: (2021)

Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole–Protein Adducts
por: Ma, Jiang, et al.
Publicado: (2021)

Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
por: Guo, Tingting, et al.
Publicado: (2019)

Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by Gynura japonica Containing Pyrrolizidine Alkaloids
por: Wang, Xunjiang, et al.
Publicado: (2021)

A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wang, Weiqian, et al.
Publicado: (2022)

Hepatic Venous Occlusion Type of Budd–Chiari Syndrome versus Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstructive Syndrome: A Multi-Center Retrospective Study
por: Tong, Yaru, et al.
Publicado: (2023)

Bioassay-directed analysis-based identification of relevant pyrrolizidine alkaloids
por: Louisse, Jochem, et al.
Publicado: (2022)

Long-Term Hemodynamic Effects of Portocaval Shunt and Sugiura Procedure in Patients with Cirrhosis
por: Vons, Corinne, et al.
Publicado: (1996)

A Case of Pulmonary Arterial Hypertension Associated with Congenital Extrahepatic Portocaval Shunt
por: Yi, Jeong-Eun, et al.
Publicado: (2014)

Pyrrolizidine Alkaloids in Food on the Italian Market
por: Peloso, Mariantonietta, et al.
Publicado: (2023)

Gut microbiota-derived tryptophan metabolites alleviate liver injury via AhR/Nrf2 activation in pyrrolizidine alkaloids-induced sinusoidal obstruction syndrome
por: Shang, Haitao, et al.
Publicado: (2023)

Hepatotoxic pyrrolizidine alkaloids induce DNA damage response in rat liver in a 28-day feeding study
por: Ebmeyer, Johanna, et al.
Publicado: (2020)

Stent angioplasty of narrowed portocaval shunt in Budd Chiari syndrome: a case report
por: Doctor, Nilesh, et al.
Publicado: (2009)

Pulmonary arterial hypertension caused by congenital extrahepatic portocaval shunt: a case report
por: Lin, Kai-yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0q0kg64vm8ocli40mcobabkrhs